Janux Therapeutics, Inc. (JANX) has initiated patient dosing in a Phase 1b clinical trial evaluating JANX011, a novel investigational therapy targeting autoimmune diseases. The trial will enroll up to 48 participants across multiple U.S. sites.
- JANX011 is being evaluated in a Phase 1b trial involving up to 48 patients with autoimmune disorders.
- The trial will assess safety, pharmacokinetics, and biomarker changes over a 12-week period.
- JANX011 targets the CD45 receptor on T cells to modulate immune response without broad immunosuppression.
- Trial sites are located across six U.S. centers, with a randomized, double-blind, placebo-controlled design.
- Interim data is expected in late 2026, with potential progression to Phase 2 if results are favorable.
- The stock ticker JANX may see short-term volatility as investors assess trial progress.
Janux Therapeutics, Inc. (JANX) has announced the start of patient dosing in a Phase 1b clinical trial evaluating JANX011, a first-in-class monoclonal antibody designed to modulate T-cell activity in autoimmune conditions. The trial is a multicenter, randomized, double-blind, placebo-controlled study assessing safety, tolerability, pharmacokinetics, and preliminary efficacy in participants with moderate to severe autoimmune diseases, including lupus and psoriasis. The study will enroll up to 48 patients, with dosing scheduled across six clinical trial sites in the United States. The initiation marks a pivotal step in the development of JANX011, which is engineered to target the CD45 receptor on T cells, aiming to reduce pathogenic immune responses without broad immunosuppression. Preclinical data demonstrated significant modulation of T-cell activity and reduced inflammatory markers in disease models. The trial will evaluate multiple dose cohorts over a 12-week period, with primary endpoints focused on safety and biomarker changes. If successful, the Phase 1b results could position JANX011 for advancement into Phase 2 trials, potentially expanding into additional autoimmune indications. The biotech’s stock, trading under the ticker JANX, may experience increased volatility in response to interim data readouts expected in the second half of 2026. This development adds to Janux’s pipeline, which includes two other programs in preclinical stages targeting neurodegenerative and inflammatory diseases.